Table 1.
The effect of paclitaxel nanoformulation against different types of cancer.
| Paclitaxel nanoformulation | Target tissue/type of cancer | Mode of delivery | Reference |
|---|---|---|---|
| Nanoformulated paclitaxel and AZD9291 | Lung cancer | AZD9291-loaded disulfide cross-linking micelles (DCMs) | [94] |
| Low-dose nanoparticle albumin-bound paclitaxel (nab-PTX) | HER2-negative metastatic breast cancer | Albumin nanoparticles | [95, 96] |
| Nab-paclitaxel–gemcitabine combination | Pancreatic cancer | Albumin nanoparticles | [97] |
| Milk-derived exosomal formulation of PAC (ExoPAC) | Lung cancer | Exosomes | [98] |
| PTX-GemC12-LNC formulation | Brain tumour (glioblastoma) | Liquid nanoparticle | [99] |
| Paclitaxel-loaded PCL-TPGS nanoparticles: PTX-loaded poly(caprolactone)–alpha-tocopheryl polyethylene glycol 1000 succinate (PCL-TPGS) NPs |
Breast cancer | PCL-TPGS copolymer | [100] |
| Paclitaxel-loaded poly(glycolide-co-ε-caprolactone)-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles (PTX-loaded (PGA-co-PCL)-b-TPGS2k | Lung cancer | Amphiphilic copolymer (PGA-co-PCL)-b-TPGS2k | [101] |
| Paclitaxel and superparamagnetic iron oxide-loaded PEGylated poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (PTX/SPIO-NPs) | Glioblastoma | Superparamagnetic iron oxide-PEGylated poly(lactic-co-glycolic acid)-based nanoparticles | [102] |
| PTX micelles | Pulmonary carcinoma | Poly(ethylene glycol)-poly(3-caprolactone) copolymers (MPEG-PCL micelles) | [103] |
| Paclitaxel-loaded vitamin E-TPGS nanoparticles | Lung cancer Breast cancer Colorectal cancer Brain cancer Prostate cancer |
TPGS nanoparticles | [75, 100, 104–107] |
| PTX nanomicelles using poly(styrene-co-maleic acid) (SMA); SMA-PTX micelles | Murine orthotopic colon cancer model | Poly(styrene-co-maleic acid) | [108] |
| Lumbrokinase/paclitaxel/poly(ethylene glycol)-b-(poly(ethylenediamine l-glutamate)-g-poly(ε-benzyoxycarbonyl-l-lysine)-r-poly(l-lysine)) LK/PTX/PEG-b-(PELG-g-(PZLL-r-PLL)) | Bladder cancer | Poly(ethylene glycol)-b-(poly(ethylenediamine l-glutamate)-g-poly(ε-benzyoxycarbonyl-l-lysine)-r-poly(l-lysine)) | [109] |
| Paclitaxel dimer-methoxypoly(ethylene glycol)2K-block-poly(D,L-lactide)2K (PTX dimer)/PEG-PDLLA formulations | Cervical cancer | Methoxypoly(ethylene glycol)2K-block-poly(D,L-lactide)2K (PEG-PDLLA) micelles | [110] |
| PTX-loaded redox-sensitive HSV nanoparticles | Lung cancer | Hyaluronic acid-disulfide-vitamin E succinate (HA-SS-VES, HSV) conjugate | [111] |
| Thermostable RNA-PTX nanoparticles (4WJ-X-24 PTX nanoparticles) | Breast cancer | RNA nanoparticles | [112] |